Sarepta Therapeutics Inc
NASDAQ:SRPT
Intrinsic Value
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. [ Read More ]
The intrinsic value of one
SRPT
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 125.465 USD,
Sarepta Therapeutics Inc
is
hidden
.
Sarepta Therapeutics Inc's market capitalization is 11.9B USD.
SRPT stock price is 125.465 USD.
SRPT stock price (125.465 USD) is 48% less than its Intrinsic Value (241.34 USD).
SRPT stock price (125.465 USD) is 56% less than its Relative Value (282.131 USD). Open Relative Valuation
SRPT has upside potential of 38% compared to the average analyst price target.
Open Wall St Estimates
SRPT's D/E (Debt to Equity) is equal to 1.18.
SRPT's ROE (Return on Equity) for the past 12 months is very low and is equal to 2%.
SRPT's long-term assets (3B USD) exceed its long-term liabilties (2B USD).
SRPT's Revenue has grown by an exceptional 44% over the past 12 months.
SRPT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -3%.
SRPT has negative Net Debt. This means that the company has more cash and short-term investments (1B USD) than debt (1B USD).
SRPT's ROE (Return on Equity) has significantly increased in the last 3 years from -84% to 2%.
SRPT's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -69% to -3%, and is approaching profitability.
SRPT's Altman Z-Score is equal to 1.84.
SRPT's Revenue is forecast to grow at a rate of 43% per year over the next 3 years.
SRPT's Revenue has been growing by an exceptional 35% per year for the last 3 years.
SRPT has negative Operating Income for the last twelve months.
SRPT has positive Net Income for the last twelve months.
SRPT has positive Gross Profit for the last twelve months.
SRPT has negative Free Cash Flow for the last twelve months.
SRPT has negative three-year average ROE (Return on Equity): -89%. The company is not efficient at transforming stockholders' equity into net income.
SRPT has negative three-year average ROIC (Return on Invested Capital): -47%. The company is not efficient at using invested capital to generate operating income.
SRPT's short-term assets (2B USD) exceed its short-term liabilties (609m USD).
SRPT doesn't generate enough operating income (-95m USD) to safely cover interest payments on its debt (16m USD).
Valuation Backtest
Sarepta Therapeutics Inc
Run backtest to discover the historical profit from buying and selling
SRPT
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Sarepta Therapeutics Inc
Balance Sheet Decomposition
Sarepta Therapeutics Inc
| Current Assets | 2.5B |
| Cash & Short-Term Investments | 1.4B |
| Receivables | 419.4m |
| Other Current Assets | 654.7m |
| Non-Current Assets | 759.5m |
| Long-Term Investments | 41.4m |
| PP&E | 375.6m |
| Intangibles | 28.9m |
| Other Non-Current Assets | 313.6m |
| Current Liabilities | 608.7m |
| Accounts Payable | 91.5m |
| Accrued Liabilities | 167.8m |
| Other Current Liabilities | 349.4m |
| Non-Current Liabilities | 1.7B |
| Long-Term Debt | 1.1B |
| Other Non-Current Liabilities | 520.8m |
Earnings Waterfall
Sarepta Therapeutics Inc
|
Revenue
|
1.4B
USD
|
|
Cost of Revenue
|
-165.8m
USD
|
|
Gross Profit
|
1.2B
USD
|
|
Operating Expenses
|
-1.3B
USD
|
|
Operating Income
|
-94.8m
USD
|
|
Other Expenses
|
111.7m
USD
|
|
Net Income
|
17m
USD
|
Free Cash Flow Analysis
Sarepta Therapeutics Inc
SRPT Profitability Score
Profitability Due Diligence
Sarepta Therapeutics Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Sarepta Therapeutics Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
SRPT Solvency Score
Solvency Due Diligence
Sarepta Therapeutics Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Sarepta Therapeutics Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SRPT Price Targets Summary
Sarepta Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
SRPT
is 172.577 USD
with a low forecast of 129.28 USD and a high forecast of 235.2 USD.
Ownership
SRPT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SRPT Price
Sarepta Therapeutics Inc
| Average Annual Return | 6.91% |
| Standard Deviation of Annual Returns | 37.16% |
| Max Drawdown | -65% |
| Market Capitalization | 11.9B USD |
| Shares Outstanding | 94 510 000 |
| Percentage of Shares Shorted | 6.3% |
SRPT News
Last Important Events
Sarepta Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Sarepta Therapeutics Inc
Company Profile
Sarepta Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 840 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (Duchenne), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) disorders. The company commercializes three products, such as EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection. These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes more than 40 programs at various stages of discovery, pre-clinical and clinical development.
Contact
IPO
Employees
Officers
The intrinsic value of one
SRPT
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 125.465 USD,
Sarepta Therapeutics Inc
is
hidden
.
You don't have any saved screeners yet
